Biotransformation Reactions
Biotransformation Reactions - Related Videos
01:16
Drug Biotransformation: Overview
0 Views •
2023
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28
Drug Biotransformation: Overview
0 Views •
2025
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
01:19
Factors Affecting Drug Biotransformation: Biological
0 Views •
2025
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity. Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects. Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:21
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
0 Views •
2025
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism. The drug's acidity or basicity is essential in determining the metabolic...
03:06
Reaction Mechanisms
0 Views •
2020
Chemical reactions often occur in a stepwise fashion, involving two or more distinct reactions taking place in a sequence. A balanced equation indicates the reacting species and the product species, but it reveals no details about how the reaction occurs at the molecular level. The reaction mechanism (or reaction path) provides details regarding the precise, step-by-step process by which a reaction occurs. For instance, the decomposition of ozone appears to follow a mechanism with two steps:
FAQs
Phase I reactions commonly introduce or expose chemical features through oxidation, reduction, or hydrolysis. Phase II reactions may then attach compounds such as glucuronic acid or sulfate, often increasing water solubility. This sequence can promote elimination, but it is not simply a detoxification pathway because the resulting metabolite may retain activity or become toxic.
The outcome depends on the chemical properties and activity of the metabolite formed. A reaction may reduce a compound’s activity and support clearance, yet another product may remain pharmacologically active or cause toxicity. Consequently, evaluating the parent compound alone can miss effects that influence therapeutic duration, adverse reactions, and overall clinical risk.
Enzyme inhibition can reduce the rate at which a compound is transformed, potentially slowing clearance and prolonging its effects. Enzyme induction can increase transformation, which may shorten therapeutic duration or alter the amount of metabolite produced. These changes create clinically important interactions because they can modify drug exposure, activity, and toxicity.
Clinicians use the expected effect of biotransformation on clearance and therapeutic duration when evaluating dose selection. Faster or slower removal can change how much active compound remains available, while active or toxic metabolites may add separate effects. These considerations help connect pharmacokinetic behavior with treatment response, adverse effects, and individualized therapy.
Metabolite assessment can indicate whether a compound is being converted into an inactive, active, or toxic product. That information helps explain therapeutic effects that persist after the original compound changes, as well as unexpected adverse effects. In clinical pharmacology, metabolite behavior therefore contributes to pharmacokinetic interpretation and toxicology assessment.
The liver is a common site where enzyme-mediated changes to drugs, toxins, and other compounds occur. Examining hepatic Phase I and Phase II activity helps researchers and clinicians evaluate clearance, expected treatment duration, and possible interactions. This knowledge supports dose selection and individualized treatment while also informing toxicology and pharmacokinetic assessments.